Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Health Care Reform Draft Sparks Strong Industry Response

This article was originally published in PharmAsia News

Executive Summary

China's latest healthcare reform draft released Oct. 14 has elicited intense response, attracting some 2,000 postings online. After calling for an emergency meeting in Beijing, principals of the nation's more than 30 pharmaceutical industry associations jointly signed an opinion draft that will be submitted to the State Council. The document focuses on the industry's concerns such as how to improve the national basic medicine and drug-pricing system, whether it is feasible to revamp the current drug bidding structure, and how to encourage pharmaceutical companies to innovate. An expert suggests that rather than restricting basic medicine manufacturing to certain parties as stated in the reform, the government may instead request medical providers to invite tenders to ensure production and supply. (Click here for more - Chinese Language)

You may also be interested in...



MNCs Against Pricing Structure Of National Basic Medicine System

R&D-based Pharmaceutical Association Committee, multinational pharma's mouthpiece in China, recently disclosed its proposal for the national health care reform plan opinion draft. RDPAC considers the plan, which designates certain enterprises to produce and market basic medicine, to go against the country's anti-monopoly principles. Local pharmaceutical industry associations hold the same view (PharmAsia News, Oct. 20, 2008). (Click here for more - Chinese language)

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

UsernamePublicRestriction

Register

WI964844

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel